Home › Research › Biomarkers
Predicting onset of Alzheimer disease symptoms with a plasma %p‐tau217 clock
Kellen K. Petersen, Marta Milà‐Alomà, Duygu Tosun, Yan Li, Benjamin A. Saef, Leslie M. Shaw, Jeffrey L. Dage, Henrik Zetterberg et al.. Alzheimer s & Dementia, 2025-12-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Abstract Background Time proxies based on blood biomarkers may facilitate understanding of the timing of biomarker change and symptom onset in Alzheimer's disease (AD) and could potentially enable biological staging of AD. Compared to CSF biomarkers or brain imaging, blood biomarkers are more accessible and less burdensome, making a “plasma clock” a practical and useful tool. Method Longitudinal plasma %p‐tau217 ( p ‐tau217 concentration divided by np‐tau217 concentration x 100) measurements from individuals enrolled in the Knight ADRC ( n = 420) or ADNI ( n = 392) cohorts were analyzed to develop plasma clocks for each cohort. The %p‐tau217 values were transformed into a time scale by integrating the inverse of the modeled rate of change. A %p‐tau217 value of 4.06%, which corresponds to amyloid PET Centiloid=20, was considered the threshold for positivity and set as time zero. The estimated age at %p‐tau217 positivity was then used to predict symptom onset, defined as a change in Clinical Dementia Rating® (CDR) from CDR=0 to CDR>0. Result The rate of change for plasma %p‐tau217 was relatively consistent between 0.65‐8.16% (Figure 1) and was used to construct independent plasma %p‐tau217 clocks for the Knight ADRC and ADNI cohorts (Figure 2). For individuals with plasma %p‐tau217 measured before and after positivity (4.06%), the estimated age at positivity based on the clock was strongly correlated with the actual age at conversion (Knight ADRC: R2=0.646, r=0.807; ADNI: R2=0.790, r=0.891). The Knight ADRC and ADNI plasma clocks provided highly similar estimates of the age at %p‐tau217 positivity for individuals in either study (adjusted R 2 =0.993, Pearson r=0.997, Figure 2). The estimated age at plasma %p‐tau217 positivity predicted the age at symptom onset (Figure 3) in the Knight ADRC (Spearman r=0.421, adjusted R 2 =0.151) and ADNI cohorts (Spearman r=0.648, adjusted R 2 =0.397). Conclusion Two independently constructed %p‐tau217 plasma clocks had strong correlations with actual time measures and were consistent across the two cohorts. Additionally, the age at %p‐tau217 positivity predicted symptom onset. Overall, these findings suggest that plasma %p‐tau217 may be useful in predicting symptom onset and in biological staging of AD.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 420 participants. Using repeated blood measurements of the tau marker %p-tau217, researchers built a 'plasma clock' that estimates when a person first becomes biomarker-positive and may help predict when Alzheimer's symptoms begin. Reported effect size: 4.06%; 8.16%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Petersen, K. K., Milà‐Alomà, M., Tosun, D., Li, Y., Saef, B. A., Shaw, L. M., et al. (2025). Predicting onset of Alzheimer disease symptoms with a plasma %p‐tau217 clock. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_099674
Vancouver
Petersen KK, Milà‐Alomà M, Tosun D, Li Y, Saef BA, Shaw LM, et al. Predicting onset of Alzheimer disease symptoms with a plasma %p‐tau217 clock. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_099674. PMID: 41442191.
BibTeX
@article{petersen2025-41442191,
author = {Petersen, Kellen K. and Milà‐Alomà, Marta and Tosun, Duygu and Li, Yan and Saef, Benjamin A. and Shaw, Leslie M. and Dage, Jeffrey L. and Zetterberg, Henrik and others},
title = {{Predicting onset of Alzheimer disease symptoms with a plasma \%p‐tau217 clock}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70856_099674},
pmid = {41442191},
url = {https://doi.org/10.1002/alz70856_099674}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Compared to CSF biomarkers or brain imaging, blood biomarkers are more accessible and less burdensome, making a “plasma clock” a practical and useful tool.
- Result The rate of change for plasma %p‐tau217 was relatively consistent between 0.65‐8.16% (Figure 1) and was used to construct independent plasma %p‐tau217 clocks for the Knight ADRC and ADNI cohorts (Figure 2).
- Overall, these findings suggest that plasma %p‐tau217 may be useful in predicting symptom onset and in biological staging of AD.
Why it matters
Using repeated blood measurements of the tau marker %p-tau217, researchers built a 'plasma clock' that estimates when a person first becomes biomarker-positive and may help predict when Alzheimer's symptoms begin. The authors suggest this approach may be useful for predicting symptom onset and for staging the disease biologically.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designlongitudinal study
- Participants420
- Effect size4.06%; 8.16%
- Evidence strengthModerate
How this study scored 52/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 420 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Suzanne Elizabeth Schindler: h-index 56 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 12 institution(s) in 4 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41442191) |
| Free to read | 2 / 2 | Free to read |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/alz70856_099674
- PubMed: 41442191
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.